Over 90% of bladder cancers are urothelial carcinomas with distinct molecular characteristics for muscle-invasive bladder cancers (MIBCs) such as TP53 mutations or non-muscle-invasive bladder cancers (NMIBCs) including activating FGFR3 mutations or PIK3CA alterations [3]. Here, FGFR3 is linked to urinary bladder cancer.